Humulin 70/30 and Cataract - a phase IV clinical study of FDA data

Summary:

Cataract is reported as a side effect among people who take Humulin 70/30 (insulin recombinant human; insulin susp isophane recombinant human), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Metformin, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Cataract when taking Humulin 70/30. It is created by eHealthMe based on reports of 5,537 people who have side effects when taking Humulin 70/30 from the FDA, and is updated regularly.

What is Humulin 70/30?

Humulin 70/30 has active ingredients of insulin recombinant human; insulin susp isophane recombinant human. It is often used in diabetes. eHealthMe is studying from 5,573 Humulin 70/30 users. Check the latest studies of Humulin 70/30.

What is Cataract?

Cataract (clouding of the lens inside the eye) is found to be associated with 1,892 drugs and 2,133 conditions by eHealthMe. Check the latest studies of Cataract.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 24, 2026

5,537 people reported to have side effects when taking Humulin 70/30.
Among them, 173 people (3.12%) have Cataract.

Among these 173 people:

* Approximation only. Some reports may have incomplete information.

Do you take Humulin 70/30 and have Cataract?

- Check whether Cataract is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Humulin 70/30:

Humulin 70/30 (5,573 reports)

Cataract treatments and more:

Cataract (70,565 reports)

How severe was Cataract and when was it recovered:

Cataract in Humulin 70/30

Expand to all the drugs that have ingredients of insulin recombinant human; insulin susp isophane recombinant human:

Cataract and drugs with ingredients of insulin recombinant human; insulin susp isophane recombinant human

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Humulin 70/30:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cataract:

Cataract (1,892 drugs)

Browse all the conditions that are associated with Cataract:

Cataract (2,133 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Dsouza MC, "Could risperidone have caused the cataract?: A case report and review of literature", Journal of Research in Psychiatry and Behavioral Science, 2015 Jan .
Dsouza MC, "COULD RISPERIDONE HAVE CAUSED THE CATARACT", JRPBS, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on insulin recombinant human; insulin susp isophane recombinant human (the active ingredients of Humulin 70/30) and Humulin 70/30 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.